Predictive algorithms for adjuvant therapy: TransATAC

Steroids

Volumn 76, Issue 8, 2011, Pages 777-780

  Dowsett, Mitch ^a   Salter, Janine ^a   Zabaglo, Lila ^a   Mallon, Elizabeth ^b   Howell, Antony ^c   Buzdar, Aman U ^d   Forbes, John ^e   Pineda, S ^f   Cuzick, Jack ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aromatase inhibitor; Endocrine therapy; Predictive algorithm

Indexed keywords

ANASTROZOLE; AROMATASE; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ALGORITHM; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROTEIN POLYMORPHISM; TUMOR VOLUME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM RECURRENCE, LOCAL; NITRILES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 79958772865     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.032     Document Type: Conference Paper

References (16)

1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. (Pubitemid 34694019)
3. Cuzick J, Sestak I,BaumM, Buzdar A, Howell A, Dowsett M, et al. 10-year analysis of the ATAC trial comparing anastrozole with tamoxifen in early breast cancer. Lancet Oncol 2010;11:1135-41.
4. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-65.
5. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
6. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
7. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7. (Pubitemid 46291814)
8. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
9. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008;100:642-8.
10. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010;28:3411-5.
11. Pfeiler G, Königsberg R, Singer CF, Seifert M, Dubsky PC, Samonigg H, et al. Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: an analysis of the ABCSC-12 trial. J Clin Oncol 2010;28:512.
12. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007;9:R81.
13. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
14. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
15. Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, et al. Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical informatin: ameta-analysis approach. J Clin Oncol 2010;28:509.
16. Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, et al. Prognostic value of a cmbined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI Recurrence Score - results from TransATAC. Cancer Res 2009;69:503s.